Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Endonovo Partners with International Distributor for SofPulse® Line
Partnership Expected to Increase SofPulse® Distribution and Revenues
Los Angeles, CA, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced a new non-exclusive stocking distributor agreement with Pulse Therapeutics Technology, Inc. (the “Distributor”) to purchase and distribute its SofPulse® medical devices into Mexico and Costa Rica.
The Distributor, recognizing the treatment potential of the SofPulse® PEMF (Pulsed Electro Magnetic Frequency) device, recently purchased in excess of $100,000 of product for testing and marketing in Mexico and Costa Rica, and the test was successful, and the stocking Distributor has placed an initial order of $300,000.
Endonovo – through its subsidiary SofPulse, Inc. – will work closely with the Distributor to provide ongoing support and training to ensure successful implementation of the SofPulse® in clinics and hospitals in the region. The Company will establish a dedicated customer service team to support its continued international expansion.
Revenue and Distribution
Ira Weisberg, President of SofPulse, Inc., commented on the announcement: “With international distribution of the SofPulse® into Mexico and Costa Rica, the Company expects to see a significant increase in quarterly revenues. The positive feedback on the product's effectiveness in reducing inflammation, pain and edema is a good indication of the product's potential success.
Weisberg continued: “The purchase of SofPulse® units by the Distributor affirms our belief that there is an international business for SofPulse® and that there is high demand for the device in these markets. This partnership, and others expected to follow, should lead to a major financial boost for the Company.”
Weisberg concluded: “The decision of an international distributor to purchase a large inventory of units and position SofPulse® as their flagship product for 2023 indicates a strong belief in the product's potential success.”
International Expansion to Continue
The Company’s “Go-to-Market” strategy for SofPulse® is continuing to move forward aggressively. The Company is presently negotiating to expand distribution of SofPulse® through additional major distribution partners in South and Central America. It is concurrently continuing licensing and distribution contract discussions with recognized distribution partners in Australia, Europe and various Southeast Asian markets.
Additionally, the SofPulse® device is expected to obtain Taiwan FDA clearance later in 2023 to sell and distribute throughout Taiwan through a previously announced partnership with Evermed Medical Enterprise Ltd.
My guess is that they keep tweaking 4.0 before official release. Every time they think it is ready...a bug is found (my guess).
It was last July when Joe tweeted 4.0 release was imminent. Joe went dark after that proclamation. Probably thinks it is best to remain quiet rather than setup expectations and then crash them when things don't go as planned.
Look what happened with Curious. Seems he was setup with expectations of news release from the shareholder meeting and nothing has been released yet.
It appears timelines are not PNNX's specialty.
Hope it is a good secretive and not a bad secretive. < grin>
Why does this have a Yield sign?
Appears current with filings.
Year end ER is not due for 90 days after Dec 31...right?
New Details on Endonovo’s Spin-Off of SofPulse, Inc.
Los Angeles, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced today details regarding the planned spin-off of its medical device assets to a newly formed Delaware company, SofPulse, Inc.
SofPulse, Inc. Will Operate Independently
SofPulse, Inc. will operate independently from Endonovo and focus on developing commercialization initiatives for its SofPulse® medical device line. The spin-off will also include Endonovo's recently-announced telehealth initiative.
The new company will be overseen by Ira Weisberg, the current President and Chief Commercial Officer of Endonovo's Medical Division, who will serve as CEO/President. He will oversee preparations for listing SofPulse, Inc. on the NASDAQ exchange.
Valuation
The planned spin-off of SofPulse, Inc. is expected to be completed later in 2023. SofPulse, Inc. will pay an amount to Endonovo as determined by a third-party valuation. Endonovo believes, as previously announced, that approximately 20% of the shares received in the spin-off will be paid to satisfy its existing debtholders with the balance principally available to existing shareholders. The spin-off is expected to result in a pre-money valuation of SofPulse, Inc. in excess of $50 million.
Endonovo is currently reviewing proposals from independent financial advisors and respected medical device valuation firms to analyze the fairness of the proposed transaction to protect stockholder interests.
Plans to Become NASDAQ Listed
SofPulse, Inc.'s management will assemble an outside Board of Directors, appoint the appropriate committee members and complete infrastructure requirements to prepare for listing on NASDAQ.
The newly formed company has recently initiated an aggressive “Go To Market” strategy aimed to take the company to over $100 million in sales by the end of 2024.
Weisberg said in making today’s announcement: “As revenues grow and we expand operations, we are committed to uplisting to a major stock exchange after the spin-off occurs. Our present ‘Go To Market’ strategy, combined with aggressive sales and marketing initiatives, are beginning to yield positive results that make our revenue goals attainable.”
Benefits of Listing on NASDAQ
From Nasdaq.com: “Since 2005, more than 400 companies worth $2.2 trillion in market cap have switched to NASDAQ. Leading innovators choose NASDAQ for capital raising, shareholder engagement and intelligence tools. NASDAQ features stringent listing requirements and regulatory oversight that stock analysts and the investing public highly regard. The electronic process for trading allows investors to trade through a transparent and computerized system. NASDAQ’s diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence.”
“We believe that moving to NASDAQ will give our company greater exposure, enhanced visibility and increased legitimacy amongst the investment community.” said Weisberg.
SofPulse® -- A Viable Alternative to Opioids
SofPulse Inc. will feature SofPulse® medical devices designed to provide a viable alternative to opioid pain management for surgical patients.
Weisberg pointed out: “We believe that through the development of our telehealth initiative we will provide non-pharmacological surgical pain solutions as well as alternative pain management options through its direct-to-consumer sales of prescription and non-prescription uses of SofPulse®. Focusing on drug-free pain management, we should be able to increase revenues in the U.S., international, active/retired military and consumer medical markets.”
About Endonovo Therapeutics, Inc.
Endonovo Therapeutics is currently structured into two divisions: Legacy – a commercial-stage developer primarily of noninvasive wearable Electroceuticals® therapeutic devices for pain relief, general wellness and wound curatives with many of its products marketed under the SofPulse® brand name; and its Build Up Strategy – acquiring complementary specialty service providers in the construction industry.
Ended up being 9M for the day!
Latin America is a great market.
Looking forward to some news.
Thanks.
There are no revenues in the just released Q ER. I suppose these supposed big buys will be based on future guidance?
When is 4.0 going to be revealed. Did they give an indication on timeframe?
Can you share the numbers they talked about? You don't have to be exact. In general, what did they discuss about the number you refer to?
It seems someone or a group may not have been happy as evidenced by the selling today.
Exactly.
That is the official Twitter account. It has past Tweets that only the company could have known. Some were forward looking about CEO letter release, etc.
That is some wacky statement of which the numbers certainly do not make sense.
Would you want them doing your taxes? LOL.
That Twitter account used to pump a business model they never succeeded in achieving. No point in using it anymore. Now they can hide all their past baseless pumping.
Endonovo Therapeutics Details Plan to Spin Off Medical Device Division as a Listed Public Company
Los Angeles, CA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB: ENDV) today announced details for its plan to spin off its current medical device division, known as NewCo, as a separate publicly-traded company. Endonovo’s other current division focuses on mergers and acquisitions (M&A) in the specialty construction sector and will seek to be uplisted to a national exchange.
Spin-Off Produces Two Publicly-Traded Companies
NewCo (the medical device division) will be run by Ira Weisberg and will focus on advancement of medical device sales while preparing to spin off as a national exchange listed company.
Endonovo’s existing M&A division will be run by Alan Collier and will focus on M&A strategy of purchasing profitable companies in the specialty construction sector with a goal of uplisting in the future.
NewCo Moving Forward
Ira Weisberg, President and Chief Commercial Officer of Endonovo's current medical division, stated: “NewCo featuring SofPulse® is going to continue moving forward with programs to capitalize on our portfolio of commercial and clinical-stage wearable therapeutic devices and IP. We will continue to aggressively build contracts with the Department of Defense, the VA and other domestic and international surgical and pain management markets. As a newly formed public company, we will have a new board of directors, new sales and marketing teams and a determined focus to bring PEMF technology to the global pain management market.”
Endonovo’s Future
Endonovo's current mergers and acquisitions division, run by CEO Alan Collier and Head of Corporate Development Garry Michael Kann, will focus on acquiring specialty service providers in the construction industry. The division has more than 50 years of experience in acquiring and running such companies and aims to provide a steady stream of revenue through its "Build Up Strategy."
The division has recently entered into a letter of intent to purchase a highly profitable commercial construction company and is working to secure financing for additional acquisitions in the specialty construction sector.
Recent Development
The M&A division has entered into a new letter of intent to purchase an additional highly profitable construction company. The target company is a market-leading specialty trade construction firm with a history of strong revenue growth and is expected to bring in over $50 million in revenue for 2021 and have an EBITDA of $13.5 million. More recent financials will be reviewed during the due diligence period.
Acquisition of the specialty trade construction company, once completed, will establish Endonovo as a diversified holding company in the specialty trade construction industry with strong historical proven revenue and profitability moving forward. Endonovo expects the completion of the target acquisition will allow NewCo to finalize the proposed spin-off and establish a strong presence in the medical device industry.
Upon completion of the spin-off, it is believed that NewCo will have a pre-money valuation in excess of $50 million. As previously announced, it is expected that approximately 20% of the shares received in the spin-off will be paid to satisfy its existing debtholders with the balance principally available to existing shareholders.
Enhanced Shareholder Value
Endonovo CEO Alan Collier said: "We are excited to bring our two divisions, the medical device division (NewCo) and the specialty construction division to the public markets and provide our shareholders with the opportunity to capitalize and invest in two separate, viable companies. We believe this spin-off will create long-term value for our shareholders as both entities continue to grow and succeed separately from each other."
About Endonovo Therapeutics, Inc.
Endonovo Therapeutics is currently structured into two divisions: Legacy – a commercial-stage developer primarily of noninvasive wearable Electroceuticals® therapeutic devices for pain relief, general wellness and wound curatives with many of its products marketed under the SofPulse® brand name; and its Build Up Strategy – acquiring complementary specialty service providers in the construction industry.
If Collier allows Ira to run the show with Sofpulse (without any interference) we just might see some positive direction that sticks. Since the hire of Ira, stock has gone from .008 to .02 in short time. That is impressive so far.
ENDV is getting a reboot. Let's see what happens. Give Ira a chance.
Just hope Collier gives him free reins.
It trades everyday except yesterday had 0 volume.
Maybe he will be responsible for the audited financials when/if they finally uplist to the QB exchange.
What is happening?
Your messages are a little cryptic.
Is there a vote to increase the A/S?
4.0 arriving today?
I am trying to access the Your Social Offers website. This morning it seemed glitchy. Now it is not loading.
Perhaps 4.0 will be revealed today?
The Twitter account with the misspelling is the official Twitter account.
It is not a troll account.
Up 28% on first trading day of the year!
Just because all 3 shells were lumped together in the past does not mean they will be acquired together as a package again. Each may have their own separate life in the future.
Don't know but it was my bid getting whacked. Wish it was a harder whack...hehe
Truly crazy this decline and the float has not even changed. Is not declining due to increased share count.
This should move upward fast when some positive news drops.
Interesting MM activity.
I enter the top Bid and OTCX keeps leapfrogging me to be the top bid. Seems to be an automated order to be the top Bid.
Then a few other MMs start moving up immediately following our lead.
What happened here? L2 is practically empty and is Pink Current. Strange look for a current stock.
Huge Bid support at .05s
Company being quiet is not helping the stock price any.
I believe Canada residents can purchase.
Looks like tax loss selling happening today.
.065 NITE on Ask has unknown quantity behind the 10K. I bought 20k and did not disappear.
Cannot post a pic from the app but 4 different MMs are at .0601 and 1 at .061
All only showing 10k shares but I'm certain their Bids are higher just not showing.
That is a little concerning.
Would be good time for company to release some some news and assist that seller <grin>
I suspected that large Bid was going to get fed. Now it is done. Release some news and let's get crankin'!!!
OMG...this is some next level craziness...
Endonovo Announces Plans for Spin-off of Medical IP and Assets
New Company To Be Formed for SofPulse® Medical Device Line
Los Angeles, CA, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced plans to affect a spin-off of its medical device assets to a new company (“NewCo”) being formed by its current President and Chief Commercial Officer of its Medical Division, Ira Weisberg.
Weisberg will be responsible for running NewCo independently from Endonovo and will develop commercialization initiatives through sales and marketing channels for NewCo utilizing the SofPulse® medical assets. Endonovo’s recently announced telehealth initiative will be included in the spin-off of NewCo.
NewCo shall pay such amount to Endonovo as determined by a third-party fairness opinion report. The payment may be in stock or note convertible into NewCo common stock. Endonovo intends to make such filings as will allow it to make special dividends of NewCo stock to its shareholders or to structure the transaction so that the stock is received contemporaneously with the spin-off. Endonovo intends to apply a portion of the shares available through the spin-off to satisfy its present debt holders. While no firm arrangements have been made, Endonovo believes that approximately 20% of the shares received in the spin-off will be paid to satisfy its existing debtholders with the balance principally available to existing shareholders. The structure of the eventual spin-off is subject to agreements with NewCo and the existing noteholders as well as other conditions.
$50 Million Projected Pre-Money Valuation
Management believes that upon completion of the spin-off, NewCo will have a pre-money valuation in excess of $50 million. Additionally, Weisberg has detailed sales and marketing plans to raise working capital through equity financing to continue the commercialization of SofPulse®. All shares distributed to ENDV shareholders shall be issued on a pro rata basis.
NewCo’s management believes it can take NewCo to more than $100 million in sales by 2024.
NewCo will assemble an outside Board of Directors and appoint the appropriate committee members and necessary infrastructure requirements to prepare itself to become a NASDAQ listed company.
Current Endonovo CEO Alan Collier said in making the announcement: “We want to make sure that all present and future stockholders will benefit fairly with the spin-off of IP and medical device assets. Having Ira Weisberg heading the direction and development of SofPulse® is a huge benefit.
“Ira is a proven medical company executive and business development specialist and has multiple success stories in working with similar types of medical companies and devices. I believe with Weisberg running the ship, SofPulse® devices will finally be able to reach the potential that the Pulsed Electro Magnetic Frequency (PEMF) technology can provide to the medical community.”
To evaluate the fairness of a proposed transaction from a financial point of view, Endonovo will seek out an independent financial advisor and a respected medical device valuation firm. They will be tasked to develop a valuation of medical Intellectual Property (IP) assets through a fairness opinion report. The last valuation report issued for SofPulse® IP and assets stated that these assets were worth $75 million in 2018.
Fairness Opinion to be Provided
The fairness opinion report will be prepared for Endonovo Therapeutics, Inc. and referenced in filings with the Securities and Exchange Commission (SEC). Once the proposed spin-off is fully structured and the necessary agreements competed, Endonovo shall prepare a 14C filing with the SEC and distribute information statements to the shareholders whereby the Chairman of the Board and the majority voting shareholders plan to have prior approval of the spin-off of the medical device assets to NewCo.
Weisberg to be NewCo CEO/President
Ira Weisberg has been designated as the CEO/President of NewCo. Weisberg has previous successes in growing multiple medical devices and pharmaceutical companies to profitability and increasing valuations of medical assets in excess of $750 million.
He has headed the development of an aggressive “go to market” business plan to commercialize the SofPulse® medical device assets to generate sales in excess of $100 million in revenue in 2024. NewCo will retain an auditor to provide an inception audit on the company
Weisberg has more than four decades of experience in healthcare and pharmaceutical management:
President and CEO of Amherst Pharmaceuticals;
Senior VP and Corporate Development Officer at Neurotrope Bioscience;
Negotiated out-licensing, supply, distribution and development agreements in excess of $100 million with major pharmaceutical companies;
Contributed to revenues for a company’s specialty product valued at $500 million while assisting building its valuation to more than $750 million;
Other medical administrative experience at: Allphavax, Inc., Lifecycle Pharma, Chugai Pharma USA, Haemacure Corporation and Aventis Behring;
Led negotiations and signed licensing agreements for strategic acquisitions, distribution and development deals for multiple companies in the medical device and pharmaceutical industry;
Positioned a company globally through negotiations and signing of multinational licensing and joint venture agreements;
Developed strategies to guide emerging medical companies in fast-growing emerging medical device and pharmaceutical markets;
Guided growth and generated revenue of more than $30 million for an IPO.
Weisberg stated: “Having SofPulse® and the opportunity to expand the commercialization of PEMF technology globally is an opportunity of a lifetime. Our plan is to position SofPulse® as the standard of care for the mitigation of pain and for the treatment of the associated edema and swelling. We are excited about the future of the SofPulse® devices as well as NewCo.”
The silence is like the high school class taught by Ben Stein in Ferris Bueller's Day Off. Anyone, Anyone! LOL
Endonovo Launches Telehealth Initiative
Expands Patient Education, Access to Non-Opioid Options for Pain Management
Los Angeles, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the launching of a new initiative to utilize its telehealth platform to educate and provide prescription and “over the counter” non-opioid pain reduction options.
The Endonovo Telehealth platform will provide alternative pain management options through its direct-to-consumer sales of prescription and non-prescription uses of their SofPulse® Pulsed Electro Magnetic Frequency (PEMF) medical device proven to reduce opioid use.
Shortage of Physicians
“There is a massive and acute shortage of primary care physicians and other healthcare specialists prompting the need for patient information and product distribution systems which only a telehealth platform can provide,” according to Endonovo President and Chief Commercial Officer Ira Weisberg.
Weisberg will head company development and implementation of strategic approaches for non-opioid pain management initiatives based on latest advances in telehealth services and related technologies.
Need for Pain Management Options
Grandviewresearch.com reports: “The U.S. telehealth market is expected to expand at a compound annual growth rate (CAGR) of 44.4% from 2022 to 2028.”
Weisberg continued: “Our market research, along with our medical partners, clearly shows that patients are actively seeking non-pharmacological pain management options for treating their acute and chronic pain conditions.
“Our initiative is targeted to utilize the latest medical market research and planning, development of a robust telehealth platform and identifying and employing a leading telehealth partners that has expertise in HIPAA compliance and a proven ability to promote the initiative effectively to potential users. Our telehealth initiative will help individuals and communities understand the risks of opioid use and alternative treatments available so they are able to make informed decisions about their treatment options.”
Weisberg also pointed out: “For the moment, “SofPulse® is our first product to be discussed on our platform. It is FDA cleared for the reduction of pain and edema (Inflammation) post-operatively and has been shown to reduce both pain and inflammation in multiple clinical applications and studies.
“The SofPulse® medical device has shown to be an effective holistic drug-free alternative to opioids for pain management which can help patients significantly reduce opioid use when dealing with acute and chronic pain conditions.”
Tweet
Endonovo Therapeutics (OTCQB: ENDV) $ENDV After virtually a complete shutdown due to the pandemic and our previous business model. We have repositioned, added a new high revenue division, and started rehiring. We expect to share many substantial updates in the coming weeks/months
Maybe it's time to light up the torches and march to the main office.
What's going on PNNX?
Unlimited supply of .008s available.
Today's volume seems to be due to ENDV creating a new Twitter profile.